Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2006-11-20
2009-02-17
Schnizer, Richard (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S461000, C435S069100, C435S320100, C544S044000, C530S300000, C530S350000
Reexamination Certificate
active
07491537
ABSTRACT:
A nucleic acid formulation for use in gene delivery comprising a nucleic acid and an anionic polymer is disclosed. Examples of the anionic polymer includes anionic amino acid polymer or poly-amino acid (such as poly-L-glutamic acid, poly-D-glutamic acid, poly-L-aspartic acid, poly-D-aspartic acid), poly-acrylic acid, polynucleotides, poly galacturonic acid, and poly vinyl sulfate.
REFERENCES:
patent: 4543252 (1985-09-01), Lehrer et al.
patent: 4675381 (1987-06-01), Bichon
patent: 4976962 (1990-12-01), Bichon et al.
patent: 5439440 (1995-08-01), Hofmann
patent: 5679647 (1997-10-01), Carson et al.
patent: 5702384 (1997-12-01), Umeyama et al.
patent: 5704908 (1998-01-01), Hofmann et al.
patent: 5749847 (1998-05-01), Zewert et al.
patent: 5856435 (1999-01-01), Bazile et al.
patent: 5904936 (1999-05-01), Huille et al.
patent: 5945290 (1999-08-01), Cowsert
patent: 6040925 (2000-03-01), Vondran, Jr. et al.
patent: 6048551 (2000-04-01), Hilfinger et al.
patent: 6096335 (2000-08-01), Thierry
patent: 6271205 (2001-08-01), Ross et al.
patent: 6383811 (2002-05-01), Wolff et al.
patent: 6413941 (2002-07-01), Garnett et al.
patent: 6654636 (2003-11-01), Dev et al.
patent: WO 94/24983 (1994-11-01), None
patent: WO 95/24929 (1995-09-01), None
patent: WO 96/21470 (1996-07-01), None
patent: WO 98/19710 (1998-05-01), None
patent: WO 00/03694 (2000-01-01), None
patent: WO 00/30618 (2000-06-01), None
patent: WO 00/78357 (2000-12-01), None
patent: WO 00/78791 (2000-12-01), None
patent: WO 01/13723 (2001-03-01), None
Trubetskoy et al.; “Layer-by-layer deposition of oppositely charged polyelectrolytes on the surface of condensed DNA particles;” Nucl. Acids Res.; vol. 27 No. 15; pp. 3090-3095; Aug. 1999.
Zhang et al.; “Expression of Naked Plasmid DNA Injected into the Afferent and Efferent Vessels of Rodent and Dog Livers;” Human Gene Therapy vol. 8; 1763-1772; Oct. 1997.
1998, Promega Biological Research Products Catalog, pp. 248 and 264.
GenBank Accession No. U47119; May 10, 2004.
Yeow et al.; “Antiviral Activities of Individual Murine IFN-a Subtypes In Vivo: Intramuscular Inection of IFN Expression Constructs Reduces Cytomegalovirus Replication;” J. Immunol.; vol. 160; pp. 2932-2939; 1998.
GenBank Accession No. AAB59737; Jun. 19, 2002.
Gen Accession No. AAA61621; Jan. 27, 1995.
Sigma Chemical Company Catalog; pp. 1742 and 1743; 1992.
Maniatis et al.; “Molecular Cloning: A Laboratory Manual;” Cold Spring Harbor Laboratory; pp. 86-95 and 448; 1982.
Abruzzese et al.; “Ligand-Dependent Regulation of lasmid-Based Transgene Expression in Vivo;” Human Gene Therapy; vol. 10; pp. 1499-1507; Jun. 10, 1999.
Aihara et al.; “Gene transfer into muscle by electroporation in vivo;” Nature Biotech; vol. 16; pp. 867-870; Sep. 1998.
Ayers et al.; “Polyacrylic acid mediated ocular delivery of ribozymes;” Journal of Controlled Release; vol. 38; pp. 167-175; 1996.
Bettan et al.; “High-Level Protein Secretion into Blood Circulation after Electric Pulse-Mediated Gene Transfer into Skeletal Muscle;” Molecular Therapy vol. 2, No. 3; pp. 204-210 Sep. 2000.
Bourne et al.; “DNA Immunization against Experimental Genital Herpes Simplex Virus Infection;” Journal of Infectious Diseases; vol. 173; pp. 800-807; Apr. 1996.
Chuah et al.; “Gene therapy for hemophilia;” Journal of Gene Medicine; vol. 3; pp. 3-20; Jan./Feb. 2001.
Connor et al.; “Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium;” Gene Therapy; vol. 8; pp. 41-48; Jan. 2001.
Davis et al.; “Direct Gene Transfer into Skeletal Muscle In Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression;” Human Gene Therapy; vol. 4; pp. 151-159; 1993.
Dekie et al.; “Poly-L-glutamic acid derivatives as vectors for gene therapy;” Journal of Controlled Release; vol. 65; pp. 187-202; 2000.
Erbacher et al.; “The reduction of the positive charges of polylysine by partial gluconoylation increases the transfection efficiency of polylysine/DNA;” Biochimica et Biophysica Acta; vol. 1324; pp. 27-36; 1997.
Fewell et al.; “Expression of factor IX in mice and hemophilic B dogs following intramuscular injection of PINC™ formulated plasmid with electroporation;” Blood; vol. 96; p. 803A; 2000.
Fakhrai et al.; “Eradication of established intracranial rat gliomas of transforming growth factor β antisense gene therapy;” Proc. Nat. Acad. Sci. USA; vol. 93; pp. 2909-2914; Apr. 1996.
Goto et al.; “Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene;” PNAS; vol. 97, No. 1; pp. 354-359: Jan. 2000.
Hagstrom et al.; “Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter;” Blood; vol. 95, No. 8; pp. 47-55; Apr. 2000.
Hagstrom et al.; “Complexes of non-cationic liposomes and histone H1 mediate efficient transfection of DNA without encapsulation;” Biochimica et Biophysica Acta; vol. 1284; pp. 47-55; 1996.
Hartikka et al.; “Sodium phosphate enhances plasmid DNA expression in vivo;” Gene Therapy; vol. 7; pp. 1171-1182; Feb. 2000.
Chao et al.; “Persistent expression of canine factor IX in hemophilia B canines;” Gene Therapy; vol. 6; pp. 1695-1704; 1999.
Herzog et al.; “Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector;” Nature Medicine; vol. 5, No. 1; pp. 56-63; Jan. 1999.
Herzog et al.; “Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus;” Proc. Natl. Acad. Sci. USA; vol. 94; pp. 5804-5809; May 1997.
Hoffman, et al.; “Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use;” Vaccine; vol. 15, No. 8; pp. 842-845; 1997.
Ichiba et al.; “Single Chain Obervation on Collapse Transition in Gian DNA Induced by Negatively-Charged Polymer;” Biochemical and Biophysical Research Communications; vol. 242; pp. 441-445; 1998.
Jaroszeski et al.; “In vivo antitumor effects of electrochemotherapy in a hepatoma model;” Biochimica et Biophysica Acta; vol. 1334; pp. 15-18; 1997.
Kay et al.; “In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs;” Science; vol. 262; pp. 117-119; Oct. 1993.
Kaufman; “Advances toward Gene Therapy for Hemophilia at the Millennium;”Human Gene Therapy; vol. 10; pp. 2091-2107; Sep. 1999.
Kumar et al.; “Genetic Vaccination: The advantages of going naked;” Nature Medicine; vol. 2, No. 8; pp. 857-859; Aug. 1996.
Lee et al.; “Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo;” Proc. Natl. Acad. Sci. USA; vol. 89; pp. 4524-4528; May 1992.
Letvin et al.; “Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination;” Proc. Natl. Acad. Sci. USA; vol. 94; pp. 9378-9383; Aug. 1997.
Levy et al.; “Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood;” Gene Therapy; vol. 3; pp. 201-211; Aug. 1995.
Liu et al.; “DMA Vaccines: A New Era in Vaccinology: Overview of DNA Vaccines;” Annals of the New York Academy of Sciences; vol. 772; pp. 15-20; Nov. 1995.
Lozier et al.; “Adenovirus-Mediated Expression of Human Coagulation Factor IX in the Rhesus Macaque Is Associated with Dose-Limiting Toxicity;” Blood; vol. 94, No. 12; pp. 3968-3975; Dec. 1999.
Luke et al.; “An OspA-Based DNA Vaccine Protects Mice against Infection with Borrelia burgdorferi;” Journal of Infectious Diseases; vol. 175; pp. 91-97; 1997
Fewell Jason G
MacLaughlin Fiona
Nicol Francois
Rolland Alain
Smith Louis C
Genetronics Biomedical Corporation
Huston Marilyn M.
Schnizer Richard
Wong Cabello Lutsch Rutherford & Brucculeri LLP
LandOfFree
Nucleic acid formulations for gene delivery and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid formulations for gene delivery and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid formulations for gene delivery and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079230